Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders [PDF]
Therapeutic Advances in Neurological Disorders, 2015 Objective: Intravenous immunoglobulin administration has long been used in the treatment of autoimmune neuromuscular disorders. Immunoglobulins may be administered by intramuscular, intravenous or subcutaneous routes.
Min-Suk Yoon +2 more
doaj +3 more sources
Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
ImmunoTargets and Therapy, 2013 Stephen Jolles Department of Immunology, University Hospital of Wales, Cardiff, UK Abstract: Immunoglobulin (Ig)-replacement therapy represents the mainstay of treatment for patients with primary antibody deficiency and is administered either ...
Jolles S
doaj +4 more sources
Use of subcutaneous immunoglobulin in inflammatory myositis. [PDF]
Rheumatol Adv Pract, 2021 Zhou AL, Maltez N, Ivory C.
europepmc +4 more sources
Trends in Pediatrics, 2023 Objective: In a large group of patients with primary immunodeficiency (PID), immunoglobulin replacement therapy is critical for infection control. There are two main methods of immunoglobulin replacement intravenous (IVIG) and subcutaneous (SCIG).
Selime Özen Bölük +9 more
doaj +1 more source
Neurophysiological Hallmarks of Axonal Degeneration in CIDP Patients: A Pilot Analysis
Brain Sciences, 2022 In this work, we aim to identify sensitive neurophysiological biomarkers of axonal degeneration in CIDP patients. A total of 16 CIDP patients, fulfilling the clinical and neurophysiological criteria for typical CIDP, treated with subcutaneous ...
Dario Ricciardi +6 more
doaj +1 more source
The Turkish Journal of Pediatrics, 2018 In recent years subcutaneous immunoglobulin is widely used for primary immunodeficient patients. Subcutaneous administration provides a more stable and higher serum immunoglobulin levels due to continuous and steady transition from lymphatics to the ...
Pınar Gür-Çetinkaya +7 more
doaj +1 more source
Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
Frontiers in Immunology, 2023 Significant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens.
Stephan von Gunten +3 more
doaj +1 more source
Subcutaneous IgG Replacement Therapy by Push in 32 Patients with Primary Immunodeficiency Diseases in Argentine [PDF]
, 2014 Introduction: Regular replacement with immunoglobulin infusions is the mainstay of treatment in the majority of primary immunodeficiencies. Several studies showed that Subcutaneous Immunoglobulin (SCIG) has similar efficacy to Intravenous Immunoglobulin (
Bezrodnik, Liliana +6 more
core +1 more source
Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study [PDF]
, 2019 We assessed the health-related quality of life (HRQoL) in CVID adults receiving different schedules of immunoglobulin replacement therapy (IgRT) by intravenous (IVIG), subcutaneous (SCIG), and facilitated (fSCIG) preparations.
Agostini, Carlo +13 more
core +2 more sources
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]
, 2020 BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai +13 more
core +1 more source